Filtered By:
Infectious Disease: COVID-19
Therapy: Thrombolytic Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 4 results found since Jan 2013.

Improving door-to-reperfusion time in acute ischemic stroke during the COVID-19 pandemic: experience from a public comprehensive stroke center in Brazil
ConclusionAcute stroke care continued to be a priority despite the COVID-19 pandemic. The implementation of a thrombolytic bolus and the start of continuous infusion on the CT scan table was the main factor that contributed to the reduction of DNT. Continuous monitoring of service times is essential for improving the quality of the stroke center and achieving better functional outcomes for patients.
Source: Frontiers in Neurology - July 10, 2023 Category: Neurology Source Type: research

Recombinant tissue plasminogen activator (rTPA) management for first onset acute Ischemic Stroke with covid -19 and non-covid -19 patients
In this study we compare the efficacy and safety of Tissue plasminogen activator (rTPA) in acute ischemic stroke (AIS) patients with or without Covid-19 infection.
Source: Journal of Stroke and Cerebrovascular Diseases - January 22, 2023 Category: Neurology Authors: Eman M Khedr, Ahmed Abdelwarith, Gehad M Moussa, Mostafa Saber Source Type: research

The effects of the coronavirus disease pandemic on intravenous thrombolytic therapy among patients with acute ischemic stroke in Dalian, China
We investigated the influence of the coronavirus disease 2019 (COVID-19) pandemic on the number of patients with acute ischemic stroke who received intravenous thrombolytic therapy (ITT) in Dalian, China, in 2...
Source: BMC Neurology - January 9, 2023 Category: Neurology Authors: Xin Pan, Shubei Ma, Xiaowen Sui, Lili Xie, Furong Li, Zhengping Cheng, Li Cui and Hongling Zhao Tags: Research Source Type: research

Safety and outcomes of intravenous thrombolytic therapy in ischemic stroke patients with COVID-19: CASCADE initiative
There is little information regarding the safety of intravenous tissue plasminogen activator (IV-tPA) in patients with stroke and COVID-19.
Source: Journal of Stroke and Cerebrovascular Diseases - September 19, 2021 Category: Neurology Authors: Payam Sasanejad, Leila Afshar Hezarkhani, Shahram Arsang-Jang, Georgios Tsivgoulis, Abdoreza Ghoreishi, Barlinn Kristian, Jan Rahmig, Mehdi Farhoudi, Elyar Sadeghi Hokmabadi, Afshin Borhani-Haghighi, Payam Sariaslani, Athena Sharifi-Razavi, Kavian Ghandeh Source Type: research